Integrating an updated high-risk multiple myeloma classification into clinical practice and clinical trial epidemiology [0.03%]
在临床实践和临床试验流行病学中应用更新的高危多发性骨髓瘤分类标准
Michael Sang Hughes,Suzanne Lentzsch
Michael Sang Hughes
Introduction: Numerous risk staging systems exist for newly diagnosed multiple myeloma (NDMM), from older models which rely purely on markers of 'tumor burden' to modern scores which incorporate tumor genetics. While the ...
Filomena Pierri,Maura Faraci,Sara Pestarino et al.
Filomena Pierri et al.
Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only available curative treatment option for hematologic manifestations of Fanconi Anemia (FA), which include bone marrow failure and hema...
Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third generation recombinant factor VIII replacement therapies within the Takeda factor VIII portfolio [0.03%]
从第一代凝血因子VIII(FVIII)转换为塔凯达第三代重组FVIII治疗的可行性和结果：事后的患者分析
Alicia Cerretani,Ian Robinson,Jonathan Shtaynberger et al.
Alicia Cerretani et al.
Background: The recent discontinuation of antihemophilic factor Method M, monoclonally purified (AHF-M) and recombinant antihemophilic factor (rAHF) requires evaluation of hemophilia A treatment strategies for some patien...
Can minimal residual disease be used to tailor therapy duration for chronic lymphocytic leukemia patients? [0.03%]
最小残留病灶能用于调整慢性淋巴细胞白血病患者的治疗时间吗？
Lindsey Roeker,Meghan C Thompson
Lindsey Roeker
Introduction: Undetectable minimal residual disease (uMRD) has emerged as a critical prognostic and potentially predictive biomarker in chronic lymphocytic leukemia (CLL), particularly in venetoclax-based time-limited reg...
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US) [0.03%]
美国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者偏好前瞻性研究及BTK抑制剂治疗属性和影响患者共同决策因素的研究
Sikander Ailawadhi,Swetha Challagulla,Todor I Totev et al.
Sikander Ailawadhi et al.
Background: A comprehensive quantitative analysis was conducted to examine patient preferences for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment attributes. ...
Approaches to the management of relapsed/refractory mantle cell lymphoma: navigating an increasingly complex therapeutic landscape [0.03%]
复发/难治套细胞淋巴瘤的治疗方法：在日趋复杂的治疗领域中寻找方向
Wan Danial Noor,Diego Villa,Chan Yoon Cheah
Wan Danial Noor
Introduction: Mantle cell lymphoma (MCL) represents a distinct subtype of mature B-cell lymphoma, considered incurable with a pattern of recurrent relapses and suboptimal responses to subsequent therapies that portends po...
Mathilde Guégan,Thierry Lamy
Mathilde Guégan
Introduction: Large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disease characterized by marked phenotypic, molecular, and clinical heterogeneity. Recent therapeutic advances and emerging clinical d...
Treosulfan-based conditioning strategies in older or frail patients undergoing allogeneic hematopoietic cell transplantation [0.03%]
用于老年或体弱患者异基因造血细胞移植的treosulfan预处理策略
Paschalis Evangelidis,Grigorios Salvaras,Anna Vardi et al.
Paschalis Evangelidis et al.
Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) constitutes the only curative option for patients with hematological malignancies. Nevertheless, older or comorbid allo-HCT recipients are at greater ...
Comparison of restrictive and liberal blood transfusion in critically ill adults: a meta-analysis and comprehensive review [0.03%]
重症患者限制性输血和自由性输血的比较：荟萃分析与综合述评
Xinying Quan,Yao Pu,Keming Xia
Xinying Quan
Background: Faced with a shortage of blood sources, clinicians have been striving to utilize blood judiciously for critically ill patients. Although some researchers have attempted to explore this issue, there is still no...
Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia [0.03%]
靶向ABL肌醇口袋：针对慢性髓系白血病的STAMP抑制剂
Hiroshi Ureshino,Shinya Kimura
Hiroshi Ureshino
Introduction: Chronic myeloid leukemia (CML) has been transformed by ATP-competitive BCR:ABL1 tyrosine kinase inhibitors (TKIs); however, resistance, intolerance, and long-term toxicity remain clinically relevant challeng...